Marker Therapeutics (MRKR) Expected to Announce Earnings on Monday

Marker Therapeutics (NASDAQ:MRKR) is anticipated to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $5.25 million for the quarter.

Marker Therapeutics Price Performance

Shares of MRKR stock opened at $1.25 on Friday. Marker Therapeutics has a 12 month low of $1.13 and a 12 month high of $5.99. The company has a 50 day simple moving average of $1.77 and a two-hundred day simple moving average of $2.80.

Insider Activity at Marker Therapeutics

In related news, major shareholder Enterprise Associates 16 New acquired 554,250 shares of Marker Therapeutics stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the transaction, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. The trade was a 51.73 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Steve Elms purchased 11,085 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the completion of the purchase, the director now directly owns 325,370 shares in the company, valued at $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $8.00 price objective on the stock. Brookline Capital Management upgraded shares of Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.